NEW YORK (GenomeWeb News) — Celera today said it will collaborate with Merck & Co. to develop molecular diagnostics for the drug maker to use in it clinical trials, which could potentially be used as companion diagnostics for Merck’s cancer drugs.
 
Terms of the deal, which is expected to wrap up at the end of Celera’s fiscal year 2008, call for the Applera unit to create assays based on gene-expression profiles that Merck identifies.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.